rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    JBSS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      John B. Sanfilippo: 3 Key Takeaways for Long-Term Investors
      8h agoYahoo FinanceJBSS
      John B. Sanfilippo & Son at southwest ideas: bars drive growth
      10h agoInvesting.comJBSS
      John B. Sanfilippo authorizes $20M buyback, $2 special dividend
      Nov 12Investing.comJBSS
      Swansea mum tries to raise £2.95m for son's dementia treatment

      The dementia treatment for children is available in the US, with funding for UK children unclear.

      Nov 8BBCJBSS
      Swansea mum tries to raise £2.95m for son's dementia treatment

      The dementia treatment for children is available in the US, with funding for UK children unclear.

      Nov 7BBCJBSSMMM
      Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
      Nov 6Yahoo FinanceJBSS
      How one family gave a critical boost to gene therapy research

      A family affected by Sanfilippo syndrome raised millions of dollars for research. The Food and Drug Administration just approved a gene therapy the support helped make possible.

      Nov 1NPRJBSSRARE
      Freedom Broker cuts John B. Sanfilippo stock price target on costs
      Oct 30Investing.comJBSS
      John B Sanfilippo & Son Inc (JBSS) (Q1 2027) Earnings Call Highlights: Volume Holds Steady ...
      Oct 30Yahoo FinanceJBSS
      John B. Sanfilippo & Son: Turnaround To Take Time, But Worth Waiting For
      Oct 30Seeking AlphaJBSS
      John B. Sanfilippo & Son Q1 Earnings Call Highlights
      Oct 29Yahoo FinanceJBSS
      John B Sanfilippo & Son Q1 2027 Earnings Call Transcript
      Oct 29BenzingaJBSS
      John B. Sanfilippo & Son, Inc. Q1 2027 Earnings Call Summary
      Oct 29Yahoo FinanceJBSS
      Sanfilippo & Son (JBSS) Misses Q1 Earnings and Revenue Estimates
      Oct 28Yahoo FinanceJBSS
      John B. Sanfilippo: Fiscal Q1 Earnings Snapshot
      Oct 28Yahoo FinanceJBSS
      John B. Sanfilippo & Son, Inc. 1st Quarter Fiscal Year 2027 Operating Results Conference Call
      Oct 21Yahoo FinanceJBSS
      Mum wants son, 5, with childhood dementia to 'experience life'

      Bobby's mum, Sophie, says she wants him to "get the most out of his short life'" after his diagnosis.

      Oct 16BBCJBSS
      Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?
      Oct 8Yahoo FinanceJBSSRARE
      Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

      RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

      Oct 5Yahoo FinanceJBSSRARE
      John B. Sanfilippo Announces Leadership Transition and Promotions

      Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailJBSS
      Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
      Oct 1Yahoo FinanceJBSS
      Childhood dementia should be more widely recognised, mother says

      An affected mother says she cannot think of a worse diagnosis for a child than childhood dementia.

      Sep 25BBCJBSS
      RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

      Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

      Sep 18Yahoo FinanceJBSSRARE
      Ultragenyx sets $3.95 million price for rare disease gene therapy

      Ultragenyx ​on Thursday set a U.S. list price of $3.95 million for its newly approved gene therapy Fayuvi, launching one of the world's most expensive drugs.

      Sep 18CNBCJBSS
      Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest - Ultragenyx Pharmaceutical (NA

      FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.

      Sep 18BenzingaJBSS
      Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
      Sep 18BenzingaJBSSRARE
      Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

      - FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage

      Sep 18Yahoo FinanceABEOJBSSRARE
      Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

      Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

      Sep 18Yahoo FinanceJBSSRAREBMY
      Ultragenyx sets $3.95 million price for rare disease gene therapy
      Sep 17ReutersJBSSRARE
      FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
      Sep 17Investing.comJBSSRARE
      Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

      FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx The Company received a Priority R

      Sep 17Yahoo FinanceJBSSRARE
      Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
      Sep 17Seeking AlphaJBSSRARE
      Ultragenyx Pharmaceutical Rises After FDA Approves Fayuvi for Sanfilippo Syndrome Type A
      Sep 17MorningstarJBSSRARE
      US FDA approves Ultragenyx's gene therapy for rare disorder
      Sep 17Yahoo FinanceJBSS
      FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
      Sep 17Yahoo FinanceJBSS
      RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares

      RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.

      Sep 16Yahoo FinanceJBSSRARE
      rocket companies names alessio sanfilippo as redfin CEO
      Aug 31Investing.comJBSSRKT
      Rocket Companies Names Alessio Sanfilippo Chief Executive Officer of Redfin

      Rocket Companies (NYSE: RKT) today announced that Alessio Sanfilippo has been named Chief Executive Officer of Redfin, effective immediately. Sanfilippo joins Redfin from Meta, where he served as Vice President of Insights for Reality Labs.

      Aug 31Yahoo FinanceJBSS
      Rocket Names Alessio Sanfilippo as Redfin CEO

      Rocket (RKT) has named Alessio Sanfilippo as chief executive officer of its Redfin unit, effective i

      Aug 31Yahoo FinanceJBSS
      John B. Sanfilippo Eyes $300M Bar Growth as CEO Transition Nears

      John B. Sanfilippo & Son (NASDAQ:JBSS) outlined plans to expand its snack bar manufacturing business while continuing to build on its private-label nut and trail mix operations, during a presentation at the IDEAS Conference. The company, a fourth-generation family-managed processor, marketer and di

      Aug 29Yahoo FinanceJBSS
      Record Sales, Shrinking Profits: The Two Faces Of John B. Sanfilippo & Sons (JBSS)

      On August 20, John B. Sanfilippo & Sons (NASDAQ:JBSS) reported a fiscal year that looked strong on paper and a fourth quarter that told a messier story. Full-year net sales hit $1.18 billion, a record, while fourth-quarter diluted earnings per share fell 38.3% to $0.71. Volume returned to growth for the first time in five […]

      Aug 28Yahoo FinanceJBSS
      John B. Sanfilippo & Son at 17th Annual Midwest IDEAS Conference: bar push
      Aug 27Investing.comJBSS
      John B. Sanfilippo & Son Highlights FY 2026 Growth

      Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.

      Aug 26The Globe and MailJBSS
      John B. Sanfilippo & Son (JBSS) Stock Sees Fair Value Cut As Margin Views Weaken

      The latest analyst update on John B. Sanfilippo & Son cuts fair value from US$109.00 to US$100.00, which is about an 8% reduction in the price target. Analysts link this shift to how they balance stronger revenue assumptions with more cautious views on margins and risk, and to where they see the stock on the current risk and reward spectrum. As you read on, you will see how these moving parts shape the evolving narrative around John B. Sanfilippo & Son and what to watch next. Stay updated as...

      Aug 25Yahoo FinanceJBSS

      This is the newest page. Registered accounts read further back.